Coronary Artery Bypass Graft Surgery News and Research

RSS

Cardiac enzyme elevations following CABG surgery is associated with worse prognosis

Patients who underwent coronary artery bypass graft surgery and had elevated levels of the cardiac enzymes creatine kinase or troponin in the 24 hours following surgery had an associated intermediate and long-term increased risk of death, according to a study in the February 9 issue of JAMA.

9 Feb 2011

Investigators find reduction in STEMI rates, but slight increase in NSTEMI incidence rates

Coronary syndromes vary in severity, ranging from unstable angina, non-ST segment elevation myocardial infarction, to ST-segment elevation myocardial infarction, the most severe diagnosis. Little data exist about changing trends in acute myocardial infarction and whether death rates are increasing or decreasing.

13 Jan 2011

20% of patients who received implantable cardioverter-defibrillators did not meet guidelines for receipt of ICD

A study that included more than 100,000 patients who received implantable cardioverter-defibrillators (ICDs) found that about 20 percent did not meet evidence-based guidelines for receipt of an ICD, and that these patients had a significantly higher risk of in-hospital death than individuals who met criteria for receiving an ICD, according to a study in the January 5 issue of JAMA.

5 Jan 2011

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

Summaries of a number of new Canadian Cardiovascular Society guidelines and position statements offering the most up to date information to support clinicians in practicing evidence-based medicine were released at the Canadian Cardiovascular Congress 2010 this week.

25 Oct 2010

Study finds wide variability in use of blood transfusions for coronary artery bypass graft surgery

A study that includes data on more than 100,000 patients who underwent coronary artery bypass graft surgery finds that there is wide variability among hospitals in the U.S. on the use of blood transfusions, without a large difference in the rate of death, suggesting that many transfusions may be unnecessary, according to a study in the October 13 issue of JAMA. Another study in this issue of JAMA examines the effect of a restrictive transfusion strategy on outcomes after cardiac surgery.

13 Oct 2010

MAQUET enrolls first patient in OPTION trial

MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, today announced enrollment of the first patient in the OPTION (Optimal Improvement of Vein Graft Patency Long Term by the Implementation Of Novel Endoscopic Harvesting Techniques) trial which is designed to assess patient outcomes using a standardized, best practices approach in endoscopic vessel harvesting (EVH) for coronary artery bypass graft surgery (CABG) compared with open vein harvesting methods.

23 Sep 2010

FDA Advisory Committee recommends approval of AstraZeneca's ticagrelor for Acute Coronary Syndromes

AstraZeneca today announced that the US Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee recommended the FDA approve AstraZeneca's investigational drug ticagrelor for the reduction of thrombotic events in patients with Acute Coronary Syndromes.

29 Jul 2010

Veiovis, Medtral New Zealand announce new partnership

Veiovis, a leading global healthcare company in the medical travel industry, announces its new partnership with Medtral New Zealand, a provider of first-rate healthcare experiences in New Zealand. The partnership further expands Veiovis' network of medical travel options across Asia and the Pacific, and provides patients with access to New Zealand's finest private hospitals and specialists.

10 Jun 2010

Study examines safety of non-invasive cardiac shock wave procedure for angina pectoris

UC San Diego Health System is enrolling a small group of patients in a two-year study to examine the safety of a non-invasive cardiac shock wave procedure for patients with chest pain caused by insufficient blood flow to the heart.

15 May 2010

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

18 Mar 2010

Boston Scientific announces results from HORIZONS AMI trial assessing Express bare-metal stent

Boston Scientific Corporation today announced results from an analysis of one-year subset data from the HORIZONS AMI trial assessing the impact of diabetes on clinical and angiographic outcomes in heart attack patients treated with the TAXUS® Express2™ Paclitaxel-Eluting Stent System or the Express® bare-metal stent.

16 Mar 2010

New trial comparing drug-eluting stents to bypass graft surgery in left main coronary artery disease patients

The announcement of a new clinical trial, EXCEL (Evaluation of Xience Prime versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization), that will compare drug-eluting stents to coronary artery bypass graft surgery in patients with left main coronary artery disease, was made today at "Optimizing PCI Outcomes: Evolving Paradigms," a symposium presented by the Cardiovascular Research Foundation.

15 Mar 2010

Bypass surgery: New method of growing arteries could lead to non-invasive option for treatment

A new method of growing arteries could lead to a "biological bypass"-or a non-invasive way to treat coronary artery disease, Yale School of Medicine researchers report with their colleagues in the April issue of Journal of Clinical Investigation.

9 Mar 2010

Ligand Pharmaceuticals acquires Metabasis Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has completed the acquisition of Metabasis Therapeutics, Inc. (NASDAQ:MBRX), following approval of the transaction by Metabasis stockholders yesterday. As a result, Ligand gains a fully funded partnership with Roche, additional pipeline assets and drug discovery technologies and resources. The transaction was first announced on October 27, 2009.

28 Jan 2010

Erectile dysfunction can be strongly related to the development of CVD

In the first study of its kind, New England Research Institutes, Inc. (NERI) in collaboration with the Division of Cardiology, San Francisco General Hospital and the University of California, San Francisco tested whether erectile dysfunction (ED) can be used to reclassify patients according to their future risk of developing cardiovascular disease (CVD) beyond traditional risk factors (such as smoking, high blood pressure, high cholesterol, etc).

20 Jan 2010

Telephone-delivered collaborative care for treatment of depression in post-CABG patients improve outcomes

Patients who received telephone-delivered collaborative care for treatment of depression after coronary artery bypass graft surgery reported greater improvement in measures of quality of life, physical functioning and mood than patients who received usual care, according to a study in the November 18 issue of JAMA. The study is being released early online because of its presentation at an American Heart Association scientific conference.

17 Nov 2009

Comparison study between pre and postoperative BNP measurements for predicting negative outcomes after CABG surgery

Results from a clinical study presented at the 2009 American Society of Anesthesiologists (ASA) Meeting suggest that elevated preoperative levels of the B-type natriuretic peptide (BNP) biomarker may predict hospital length of stay and mortality after primary coronary artery bypass graft surgery better than measurements of elevated postoperative BNP levels.

26 Oct 2009

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.

19 Oct 2009

Heart surgery can be scheduled anytime: Study

The October issue of the journal Anesthesiology contains a study reviewing potential adverse effects associated with the timing of a patient's heart surgery; but based on this study, there is no bad time of the day or week or year to have elective coronary artery bypass graft surgery.

23 Sep 2009